The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Nose-to-Brain Delivery
Open accessAbstract
The global prevalence of neurologic disorders is rising, and yet we are still unable to deliver most drug molecules, in therapeutic quantities, to the brain. The blood brain barrier consists of a tight layer of endothelial cells surrounded by astrocyte foot processes, and these anatomic features constitute a significant barrier to drug transport from the blood to the brain. One way to bypass the blood brain barrier and thus treat diseases of the brain is to use the nasal route of administration and deposit drugs at the olfactory region of the nares, from where they travel to the brain via mechanisms that are still not clearly understood, with travel across nerve fibers and travel via a perivascular pathway both being hypothesized. The nose-to-brain route has been demonstrated repeatedly in preclinical models, with both solution and particulate formulations. The nose-to-brain route has also been demonstrated in human studies with solution and particle formulations. The entry of device manufacturers into the arena will enable the benefits of this delivery route to become translated into approved products. The key factors that determine the efficacy of delivery via this route include the following: delivery to the olfactory area of the nares as opposed to the respiratory region, a longer retention time at the nasal mucosal surface, penetration enhancement of the active through the nasal epithelia, and a reduction in drug metabolism in the nasal cavity. Indications where nose-to-brain products are likely to emerge first include the following: neurodegeneration, post-traumatic stress disorder, pain, and glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386 · cited 1×
“The burden of neurologic diseases is rising, with unipolar and depressive disorders predicted to become the second largest cause of morbidity by 2030 (Mathers and Loncar, 2006).”
BackgroundFeigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Feigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Abyu, G. Y., Ahmed, M. B., Aichour, A. N., Aichour, I., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30299-5 · Cited by 2,275
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism
Parker, K. J., Oztan, O., Libove, R. A., Sumiyoshi, R. D., Jackson, L. P., Karhson, D. S., Summers, J. E., Hinman, K. E., Motonaga, K. S., Phillips, J. M., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705521114 · Cited by 349 · cited 9×
“Simply dissolving the drug molecule in an aqueous phase has been used to administer molecules via the nose-to-brain route (Born et al., 2002; Thorne et al., 2008; Craft et al., 2012; Parker et al., 2017).”
BackgroundMethodInfluentialCraft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335
Intranasal Treatment of Central Nervous System Dysfunction in Humans
Chapman, C. D., Frey, W. H., Craft, S., Danielyan, L., Hallschmid, M., Schiöth, H. B., & Benedict, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0915-1 · Cited by 310
Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, J., & Kern, W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301193 · Cited by 302
Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles
Ahmad, E., Feng, Y., Qi, J., Fan, W., Ma, Y., He, H., Xia, F., Dong, X., Zhao, W., Lu, Y., et al. (2017) · Nanoscale · doi:10.1039/c6nr07581a · Cited by 194
van Zuiden, M., Frijling, J. L., Nawijn, L., Koch, S. B. J., Goslings, J. C., Luitse, J. S., Biesheuvel, T. H., Honig, A., Veltman, D. J., & Olff, M. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.11.012 · Cited by 134
Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion
Abdou, E. M., Kandil, S. M., & Miniawy, H. M. F. E. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.030 · Cited by 124
Shah, B., Khunt, D., Misra, M., & Padh, H. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.04.076 · Cited by 112 · cited 2×
“09% when dosed as chitosan–tripolyphosphate nanoparticles (Shah et al., 2016).”
BackgroundDelivery of oxytocin to the brain for the treatment of autism spectrum disorder by nasal application
Tanaka, A., Furubayashi, T., Arai, M., Inoue, D., Kimura, S., Kiriyama, A., Kusamori, K., Katsumi, H., Yutani, R., Sakane, T., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00991 · Cited by 104
Hamidovic, A., Khafaja, M., Brandon, V, Anderson, J., Ray, G., Allan, A. M., & Burge, M. R. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.234 · Cited by 24
Cited by
Costa, C. P., Moreira, J. N., Sousa Lobo, J. M., & Silva, A. C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.012 · Cited by 303
Dendrimer-Based Drug Delivery Systems for Brain Targeting
Zhu, Y., Liu, C., & Pang, Z. (2019) · Biomolecules · doi:10.3390/biom9120790 · Cited by 220
Advances in human oxytocin measurement: challenges and proposed solutions
Tabak, B. A., Leng, G., Szeto, A., Parker, K. J., Verbalis, J. G., Ziegler, T. E., Lee, M. R., Neumann, I. D., & Mendez, A. J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01719-z · Cited by 170
Harnessing cerebrospinal fluid circulation for drug delivery to brain tissues
Naseri Kouzehgarani, G., Feldsien, T., Engelhard, H. H., Mirakhur, K. K., Phipps, C., Nimmrich, V., Clausznitzer, D., & Lefebvre, D. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.002 · Cited by 95
Engineered extracellular vesicles as brain therapeutics
Lino, M. M., Simões, S., Tomatis, F., Albino, I., Barrera, A., Vivien, D., Sobrino, T., & Ferreira, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.037 · Cited by 68
Metadata
- Authors
- Wang, Z., Xiong, G., Tsang, W. C., Schätzlein, A. G., & Uchegbu, I. F.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 370
- Issue
- 3
- Pages
- 593-601
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2946564651
- Cited by
- 231
- References
- 19
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.